Fig. 6: Longitudinal binding and neutralizing activity of DMAb expressed in vivo against SARS-CoV-2.

a–c, A DMAb-specific RBD binding assay (left) was developed, in which an anti-YTE antibody was used to capture DMAbs from participant sera followed by probing with biotinylated ancestral Spike RBDs. Graphs are plotted as the AUC × 1,000 for individual participants in each cohort; group means are shown in dark blue. To evaluate antiviral activity, DMAbs were purified from individual participant sera collected either before (day 0) or after (pooled from weeks 12–52) administration using anti-YTE-coated Dynabeads. Purified samples were run in the pseudovirus neutralization assay (right) either unconcentrated or concentrated to be in the range of the assay. The graphs depict the percentage (%) neutralization of individual samples at day 0 (black lines) and after DMAb delivery (colors) when tested at the indicated dilution. Group means are shown in dark blue. RBD binding activity (left) and pseudovirus neutralization (right) are shown for the single-dose cohorts (A1/A2) (a), the two-dose cohorts (B–E) (b) and the four-dose cohort (G) (c). d, Average IC₅₀ (ng ml⁻¹) of purified DMAbs from the indicated cohorts, calculated as the group geometric mean + 95% confidence interval (CI).